- Home
- SKE vs CGON Comparison
SKE vs CGON Comparison
Compare SKE & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKE
- CGON
- Stock Information
- Founded
- SKE 1979
- CGON 2010
- Country
- SKE Canada
- CGON United States
- Employees
- SKE N/A
- CGON N/A
- Industry
- SKE Precious Metals
- CGON
- Sector
- SKE Basic Materials
- CGON
- Exchange
- SKE Nasdaq
- CGON NYSE
- Market Cap
- SKE 1.4B
- CGON 1.3B
- IPO Year
- SKE N/A
- CGON 2024
- Fundamental
- Price
- SKE $14.33
- CGON $26.79
- Analyst Decision
- SKE
- CGON Strong Buy
- Analyst Count
- SKE 0
- CGON 10
- Target Price
- SKE N/A
- CGON $64.00
- AVG Volume (30 Days)
- SKE 431.4K
- CGON 1.4M
- Earning Date
- SKE 06-10-2025
- CGON 05-13-2025
- Dividend Yield
- SKE N/A
- CGON N/A
- EPS Growth
- SKE N/A
- CGON N/A
- EPS
- SKE N/A
- CGON N/A
- Revenue
- SKE N/A
- CGON $662,000.00
- Revenue This Year
- SKE N/A
- CGON N/A
- Revenue Next Year
- SKE N/A
- CGON $12,387.03
- P/E Ratio
- SKE N/A
- CGON N/A
- Revenue Growth
- SKE N/A
- CGON 224.51
- 52 Week Low
- SKE $4.10
- CGON $14.80
- 52 Week High
- SKE $14.43
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- SKE 71.04
- CGON 57.79
- Support Level
- SKE $12.39
- CGON $24.95
- Resistance Level
- SKE $12.91
- CGON $26.60
- Average True Range (ATR)
- SKE 0.56
- CGON 1.36
- MACD
- SKE 0.17
- CGON 0.06
- Stochastic Oscillator
- SKE 97.15
- CGON 73.21
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.